ES2549192T3 - Construcción de expresión de ADN - Google Patents

Construcción de expresión de ADN Download PDF

Info

Publication number
ES2549192T3
ES2549192T3 ES11801756.5T ES11801756T ES2549192T3 ES 2549192 T3 ES2549192 T3 ES 2549192T3 ES 11801756 T ES11801756 T ES 11801756T ES 2549192 T3 ES2549192 T3 ES 2549192T3
Authority
ES
Spain
Prior art keywords
dna
dna expression
construct
expression construction
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11801756.5T
Other languages
English (en)
Inventor
Matthias Schroff
Christiane Kleuss
Kerstin KAPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mologen AG
Original Assignee
Mologen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2549192(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mologen AG filed Critical Mologen AG
Application granted granted Critical
Publication of ES2549192T3 publication Critical patent/ES2549192T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Una construcción de ADN para expresión génica, en la que la construcción es una doble cadena de ADN lineal y de cadena abierta que comprende una secuencia promotora, una secuencia de codificación y una señal de terminación, en donde la construcción comprende al menos un nucleótido L-ADN y en la que al menos un nucleótido L-ADN está comprendido en el interior de los cinco últimos nucleótidos de un extremo 5' y/o 3'.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES11801756.5T 2010-12-23 2011-12-23 Construcción de expresión de ADN Active ES2549192T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201021873 2010-12-23
GBGB1021873.3A GB201021873D0 (en) 2010-12-23 2010-12-23 DNA expression construct
PCT/EP2011/073984 WO2012085282A1 (en) 2010-12-23 2011-12-23 Dna expression construct

Publications (1)

Publication Number Publication Date
ES2549192T3 true ES2549192T3 (es) 2015-10-23

Family

ID=43598917

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11801756.5T Active ES2549192T3 (es) 2010-12-23 2011-12-23 Construcción de expresión de ADN

Country Status (19)

Country Link
US (1) US20130287814A1 (es)
EP (1) EP2655620B1 (es)
JP (2) JP6377349B2 (es)
KR (1) KR101517365B1 (es)
CN (1) CN103370413B (es)
AU (1) AU2011347086B2 (es)
BR (1) BR112013015819A2 (es)
CA (1) CA2822367A1 (es)
DK (1) DK2655620T3 (es)
ES (1) ES2549192T3 (es)
GB (1) GB201021873D0 (es)
IL (1) IL227104A (es)
MX (1) MX343699B (es)
PL (1) PL2655620T3 (es)
PT (1) PT2655620E (es)
RU (1) RU2604186C2 (es)
SG (1) SG191327A1 (es)
WO (1) WO2012085282A1 (es)
ZA (1) ZA201304998B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201021873D0 (en) * 2010-12-23 2011-02-02 Mologen Ag DNA expression construct
EP3164113B1 (en) 2014-06-04 2019-03-27 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) * 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR20220046691A (ko) * 2019-08-22 2022-04-14 내셔널 유니버시티 오브 싱가포르 덤벨 모양 dna 벡터의 생성 방법
EP3854419A1 (en) * 2020-01-24 2021-07-28 Univerzita Karlova, Lekarska fakulta v Plzni Dna conjugate and method of transformation of genes into cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2138553C1 (ru) * 1991-09-30 1999-09-27 Берингер Ингельгейм Интернациональ ГмбХ Трансфекционная композиция для высших эукариотных клеток, комплекс нуклеиновой кислоты, пригодный в качестве компонента трансфекционной композиции, конъюгат, пригодный в качестве компонента трансфекционной композиции, эндосомолитический пептид, пригодный в качестве компонента трансфекционной композиции
TW480282B (en) * 1996-04-24 2002-03-21 Ren Wen Corp Recombinant eucaryotic vector containing allergen gene and use of preventing and treating allergic disease thereof
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
AU2002324909A1 (en) * 2001-09-07 2003-03-24 Baylor College Of Medicine Linear dna fragments for gene expression
ATE352632T1 (de) * 2002-07-19 2007-02-15 Mologen Ag Dna-expressionskonstrukt zur multiplen genexpression
CN1953992A (zh) * 2004-06-23 2007-04-25 Usv有限公司 源自胎盘和脑垂体同种型的嵌合体人生长激素和获得所述嵌合体的方法
WO2009035554A2 (en) * 2007-09-07 2009-03-19 University Of Florida Research Foundation, Inc. Superior structure stability and selectivity of hairpin nucleic acid probes with an l-dna stem
GB201021873D0 (en) * 2010-12-23 2011-02-02 Mologen Ag DNA expression construct

Also Published As

Publication number Publication date
SG191327A1 (en) 2013-07-31
JP6377349B2 (ja) 2018-08-22
PL2655620T3 (pl) 2016-01-29
DK2655620T3 (en) 2015-11-09
RU2604186C2 (ru) 2016-12-10
CN103370413B (zh) 2016-06-01
RU2013132149A (ru) 2015-01-27
US20130287814A1 (en) 2013-10-31
BR112013015819A2 (pt) 2018-05-29
CN103370413A (zh) 2013-10-23
EP2655620A1 (en) 2013-10-30
JP2014508512A (ja) 2014-04-10
MX2013007285A (es) 2013-09-26
GB201021873D0 (en) 2011-02-02
JP2018007669A (ja) 2018-01-18
ZA201304998B (en) 2014-03-26
HK1188608A1 (en) 2014-05-09
EP2655620B1 (en) 2015-08-12
IL227104A (en) 2017-02-28
KR20130107350A (ko) 2013-10-01
MX343699B (es) 2016-11-16
WO2012085282A1 (en) 2012-06-28
AU2011347086A1 (en) 2013-07-25
KR101517365B1 (ko) 2015-05-06
CA2822367A1 (en) 2012-06-28
PT2655620E (pt) 2015-10-26
AU2011347086B2 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
CL2012001068A1 (es) Polinucleotido que codifica oleosina modificada incluyendo al menos una cisteina introducida artificialmente, constructo genetico que comprende dicho polinucleotido; célula huesped; composicion que comprende un cuerpo oleoso; alimento animal que comprende el cuerpo oleoso.
BRPI0817811A2 (pt) Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas.
AR090869A1 (es) COMPOSICIONES DE ARNi DE SERPINC1 Y SUS METODOS DE USO
BRPI1010578A2 (pt) cartuchos de barbear ou depilar com uma pluralidade de arranjos.
EP2243811A4 (en) Core-shell quantum dot fluorescent fine particle
AR079883A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
AR079881A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
AR079882A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
MX2010010600A (es) Composiciones y metodos para secuenciacion de acidos nucleicos.
ES2566033T3 (es) Parvovirus recombinante atenuado
NI201001032A (es) Formas crsitalinas de dimetoxi docetaxel y metodo para preparar el mismo.
BRPI0906066A2 (pt) Beta-xilosidases térmicas e ácidos tolerantes, codificação de genes, organismos relacionados e métodos
BRPI0811610A2 (pt) Aço com baixa densidade, apresentando uma boa aptidão ao encaixe
CL2011001128A1 (es) Molecula de acido ribonucleico de doble cadena capaz de inhibir la expresion del gen del factor vii; secuencia de acido nucleico que codifica una cadena sentido y/o una cadena antisentido que estan comprendidas en dicha molecula de acido ribonucleico; composicion farmaceutica y su uso para tratar enfermedades tromboembolicas.
CY1124624T1 (el) Μητρες οι οποιες περιεχουν εναν τροποποιημενο πολυσακχαριτη
BR112012008053A2 (pt) fermentação purificação de heparosano k5.
BRPI0813409A2 (pt) Melões resistentes à subspécie 1,2 de f. oxysporum f. sp. melonis
MX343699B (es) Construcción de expresión de adn.
BRPI0920341A2 (pt) cilindro para freio pneumático.
DK2310499T3 (da) Mikroorganisme, der udtrykker aldose-1-epimerase
ES2599153T3 (es) Molécula de ARNi para la timidilato sintasa y uso de la misma
CL2021002842A1 (es) Moléculas inhibidoras de ácido nucleico bicatenario con cadenas de sentido acortadas
IT1393191B1 (it) Struttura di raffreddamento per una trasmissione a variazione continua del tipo a cinghia.
JP2012513655A5 (es)
EP2171046A4 (en) BACTERIOPHAGE WITH REINFORCED LYSE ACTIVITY